Advances in Radiation Therapy for Head and Neck Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 145
Special Issue Editor
Interests: head and neck cancer; breast cancer; prostate cancer; skin cancer; quality assurance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Head and neck (HN) cancer represents is of the most common types of neoplasia all over the world. Beyond surgical resection, if possible, radiotherapy (RT) is generally the treatment of choice, while almost 75% of patients will benefit from irradiation. In the early stages of HN cancer, radiotherapy can replace the need for surgical resection. Cancer patients can be treated concomitantly with chemoradiotherapy for local advanced cancer or with surgical resection followed by adjuvant radiotherapy. Over the last few decades, technology has rapidly improved, with new techniques such as intensity-modulated RT (IMRT), image-guided RT (IGRT), proton therapy, and magnetic-resonance-guided RT (MR-LINAC) now included in routine clinical practice, further improving the quality of life for cancer patients. Moreover, adaptive RT and artificial intelligence (AI) have shown excellent results following the improvement of clinical practice in terms of time-consuming procedures. Nanoparticles and hyperthermia, along with immunotherapy, have also been reported as adjuvant modalities used for improving responses to RT treatment. Re-irradiation remains a crucial subject with new data available. Alternative schemes of RT, such as hyper- or hypo-fractionation, have also shown really impressive results, while radiobiology plays an important role for RT.
Dr. Vassilis Kouloulias
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adaptive radiotherapy
- hyper- and hypo-fractionated radiotherapy
- artificial intelligence in radiotherapy for head and neck cancer
- quality assurance and set-up errors associated with IMRT, VMAT, IGRT, and SGRT techniques
- protons and heavy ions for radiotherapy
- re-irradiation
- nanoparticles plus radiotherapy
- hyperthermia plus radiotherapy
- radiotherapy plus immunotherapy
- the de-escalation of radiation therapy
